iBio (IBIO) entered into an asset purchase agreement with Otsuka Pharmaceutical Co., (OTSKY), pursuant to which Otsuka acquired iBio’s assets related to its early-stage programmed cell death protein 1 agonist program. The transaction closed on February 25, 2024. Under the terms of the Agreement, iBio will receive an upfront payment of $1.0 million in cash at closing. iBio will also be eligible to receive additional contingent cash payments totaling up to $52.5 million upon the achievement of certain pre-specified clinical development and commercial milestones.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IBIO:
- iBio Announces Sale of Preclinical PD-1 Agonist Antibody Program to Otsuka
- iBio Announces Participation in 23rd Annual PepTalk Conference
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue